Nephrology
SR | Interventions for preventing and treating kidney disease in IgA vasculitis
3 Mar, 2023 | 13:47h | UTCInterventions for preventing and treating kidney disease in IgA vasculitis – Cochrane Library
RCT | Endovascular ultrasound renal denervation is modestly effective in the treatment of hypertension
1 Mar, 2023 | 14:11h | UTCSummary: The RADIANCE II randomized clinical trial investigated the efficacy and safety of endovascular ultrasound renal denervation in patients with hypertension without the influence of antihypertensive medications. The trial enrolled 224 patients who were withdrawn from such medications and randomly assigned to receive either ultrasound renal denervation or a sham procedure. Results showed that ultrasound renal denervation reduced ambulatory systolic blood pressure by 6.3 mmHg on average at 2 months, compared to the sham procedure, without any reported adverse events. While these findings suggest that ultrasound renal denervation may be modestly effective in the treatment of hypertension, the short-term follow-up period limits the generalizability of these results to daily practice. Additionally, the clinical relevance of a procedure that reduces blood pressure only after withdrawing blood pressure medications should be considered.
Article: Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Is There a Role for Renal Denervation in the Treatment of Hypertension? – JAMA Cardiology (free for a limited period)
Pooled analysis of 3 sham-controlled trials on ultrasound renal denervation for patients with hypertension
1 Mar, 2023 | 14:10h | UTCSummary: The article reports a patient-level pooled analysis of 3 randomized clinical trials that aimed to determine the effectiveness and safety of ultrasound renal denervation (uRDN) in reducing blood pressure (BP) compared to a sham procedure. The analysis included 506 patients with varying severities of hypertension and found that uRDN was modestly effective in reducing daytime ambulatory systolic BP at 2 months compared to the sham procedure, with a mean difference of 5.9 mmHg. One of the limitations of this analysis is that its findings are restricted to a 2-month follow-up. Additional follow-up from the included trials will be required to examine the durability of the effect and safety data.
Editorial: Is There a Role for Renal Denervation in the Treatment of Hypertension? – JAMA Cardiology (free for a limited period)
M-A | Application of enhanced recovery after surgery in partial nephrectomy for renal tumors
28 Feb, 2023 | 13:46h | UTCRelated:
Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines
Consensus Report | Sepsis-associated acute kidney injury
27 Feb, 2023 | 13:05h | UTCSepsis-associated acute kidney injury: consensus report of the 28th Acute Disease Quality Initiative workgroup – Nature Reviews Nephrology (if the link is paywalled, try this one)
Commentary on Twitter
A Primer in @DiseasePrimers summarizes the epidemiology, mechanisms, diagnosis and treatment of pre-eclampsia, and discusses patient quality of life and open research questions for this condition. https://t.co/IO3uchSl8b pic.twitter.com/Y7Ij6jmy5a
— Nature Portfolio (@NaturePortfolio) February 25, 2023
Onconephrology 2022: an update
27 Feb, 2023 | 12:58h | UTCOnconephrology 2022: An Update – Kidney360
Related:
Treatment of acute kidney injury in cancer patients – Clinical Kidney Journal
Onconephrology: Update in Anticancer Drug-Related Nephrotoxicity – Nephron
SR | Clinicopathological features of kidney injury related to immune checkpoint inhibitors
27 Feb, 2023 | 12:56h | UTCRelated:
Onconephrology 2022: An Update – Kidney360
Treatment of acute kidney injury in cancer patients – Clinical Kidney Journal
Onconephrology: Update in Anticancer Drug-Related Nephrotoxicity – Nephron
[Not published yet] M-A | Too little sodium can be harmful to heart failure patients
24 Feb, 2023 | 13:59h | UTCSummary: New research presented at the American College of Cardiology’s annual scientific session suggests that heart failure patients restricting their dietary sodium intake to levels below the standard recommended maximum of 2.3 grams per day do not have additional benefits and may be at increased risk of death. The study analyzed nine randomized controlled trials that assessed different levels of sodium restriction and found that patients following a diet with a sodium intake target below 2.5 grams per day were 80% more likely to die than those following a diet with a target of 2.5 grams per day or more. The researchers recommend establishing a safe level of sodium consumption instead of overly restricting sodium.
News release: Too Little Sodium Can be Harmful to Heart Failure Patients – American College of Cardiology
Cohort Study | Heavy coffee intake is associated with kidney disfunction in genetically predisposed individuals
24 Feb, 2023 | 13:42h | UTCSummary: The study investigated whether a person’s genetic variation in the enzyme that metabolizes caffeine, called CYP1A2, modifies the association between coffee intake and kidney dysfunction. The study was conducted on 1180 participants with stage 1 hypertension. Data were collected from April 1, 1990, to June 30, 2006, with a follow-up of approximately 10 years. The study found that consuming more than three cups of coffee per day was associated with increased risks of albuminuria, hyperfiltration, and hypertension only among slow metabolizers of caffeine. The findings suggest that caffeine may play a role in the development of kidney disease in genetically susceptible individuals, but further studies are required to confirm these findings.
Article: CYP1A2 Genetic Variation, Coffee Intake, and Kidney Dysfunction – JAMA Network Open
Commentaries:
Drinking 3 or more cups of coffee daily may increase kidney dysfunction risk – Medical News Today
Consensus Statement | Renal denervation in the management of hypertension in adults
21 Feb, 2023 | 11:45h | UTC
M-A | Blood pressure lowering effects of B-blockers as add-on or combination therapy
16 Feb, 2023 | 15:10h | UTC
M-A | Relative safety and effectiveness of different erythropoiesis‐stimulating agents for anemia in adults with CKD
15 Feb, 2023 | 15:58h | UTCSummary: The article reviewed the evidence on the safety and effectiveness of different epoetin drugs in treating anemia in people with chronic kidney disease. From the available research, it is uncertain whether various epoetin medications are superior or inferior to each other in terms of the probability of requiring a blood transfusion, mortality, experiencing a heart attack or stroke, developing a clot in a fistula or dialysis vascular catheter, or the likelihood of requiring dialysis for individuals with less severe kidney disease.*
*Note: This summary was created through the collaboration of a medical editor and ChatGPT.
SR | Effect of remote patient monitoring for patients with chronic kidney disease who perform dialysis at home
15 Feb, 2023 | 15:47h | UTC
Study shows non-diabetic kidney disease is prevalent among individuals with diabetes undergoing renal biopsy
15 Feb, 2023 | 15:41h | UTCCommentary: Non-Diabetic Kidney Disease Prevalent in Individuals With Type 2 Diabetes – Consultant 360
Extracorporeal treatment for ethylene glycol poisoning: systematic review and recommendations
13 Feb, 2023 | 12:44h | UTC
Resistant hypertension: a stepwise approach
10 Feb, 2023 | 13:58h | UTCResistant hypertension: A stepwise approach – Cleveland Clinic Journal of Medicine
RCT | Effectiveness of Mycophenolate Mofetil among patients with progressive IgA nephropathy
10 Feb, 2023 | 13:52h | UTC
Commentary on Twitter
RCT: For patients with IgA nephropathy at high risk of disease progression, addition of mycophenolate to optimized supportive care reduced risk of kidney function loss, vs supportive care alone. https://t.co/xjyD3hseG7 pic.twitter.com/BlQiXkyBLn
— JAMA Network Open (@JAMANetworkOpen) February 6, 2023
RCT | Effects of Bardoxolone Methyl in Alport Syndrome
9 Feb, 2023 | 13:43h | UTC
Commentary on Twitter (thread – click for more)
✳️ #TenTweetNephJC ✳️
This week CARDINAL – the largest ever RCT in patients with Alport Syndrome 🧵👇 pic.twitter.com/wrAxJoz1GJ
— Nephrology Journal Club (@NephJC) January 28, 2023
Brief Review | Acute kidney injury
9 Feb, 2023 | 13:25h | UTCAcute kidney injury – Intensive Care Medicine
Commentary on Twitter
Acute kidney injury
🫘 contributing mechanisms
🫘 emerging trends
Deeper understanding of complex pathophysiology offers opportunities for new therapies & reno-protective strategies, supported by tools to accurately measure kidney function in real time.
🗞️ https://t.co/9RdU5AFD68 pic.twitter.com/LYgt9d21EQ— Intensive Care Medicine (@yourICM) January 3, 2023
Crossover RCT | Effects of SGLT2 inhibition on sodium in patients with chronic syndrome of inappropriate antidiuresis
8 Feb, 2023 | 12:34h | UTC
Commentary on Twitter
The syndrome of inappropriate antidiuresis (SIAD) is a major cause of hypotonic hyponatremia. This study shows the SGLT2 inhibitor empagliflozin is a promising new treatment for chronic SIAD-induced hyponatremia, possibly improving neurocognitive function https://t.co/U26RNmVM9j pic.twitter.com/8pH6xqSs7D
— JASN_News (@JASN_News) December 12, 2022
Home dialysis: conclusions from a KDIGO controversies conference
7 Feb, 2023 | 14:03h | UTC
RCT | Machine perfusion is superior to therapeutic hypothermia for reducing delayed graft function after kidney transplantation
6 Feb, 2023 | 13:28h | UTCHypothermia or Machine Perfusion in Kidney Donors – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Machine Perfusion of Kidneys Protects Against Delayed Graft Function – HealthDay
Commentary with video on Twitter
Hypothermia of brain-dead kidney donors and machine perfusion of the kidney can reduce delayed graft function, but whether hypothermia is as effective as machine perfusion is unclear. New research findings are summarized in a short video. https://t.co/mL0YQZYoK1 pic.twitter.com/ANnJl27mkl
— NEJM (@NEJM) February 4, 2023
Guideline | Management of “CKD-PeriDialysis”-the periods prior to and in the early-stage of initial dialysis
1 Feb, 2023 | 13:21h | UTC
Global, regional, and national burden of CKD due to glomerulonephritis from 1990 to 2019
1 Feb, 2023 | 13:10h | UTC
M-A | Effects of GLP-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and CKD
1 Feb, 2023 | 13:06h | UTC